EP1308461A3 - Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations - Google Patents

Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations Download PDF

Info

Publication number
EP1308461A3
EP1308461A3 EP02027099A EP02027099A EP1308461A3 EP 1308461 A3 EP1308461 A3 EP 1308461A3 EP 02027099 A EP02027099 A EP 02027099A EP 02027099 A EP02027099 A EP 02027099A EP 1308461 A3 EP1308461 A3 EP 1308461A3
Authority
EP
European Patent Office
Prior art keywords
amyloids
antibodies
derivatives
useful
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02027099A
Other languages
German (de)
English (en)
Other versions
EP1308461A2 (fr
Inventor
Nobuhiro Suzuki
Asano Asami
Chieko Kitada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27455331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1308461(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of EP1308461A2 publication Critical patent/EP1308461A2/fr
Publication of EP1308461A3 publication Critical patent/EP1308461A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP02027099A 1993-01-25 1994-01-24 Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations Withdrawn EP1308461A3 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP1013293 1993-01-25
JP1013293 1993-01-25
JP1903593 1993-02-05
JP1903593 1993-02-05
JP28698593 1993-11-16
JP28698593 1993-11-16
JP33477393 1993-12-28
JP33477393 1993-12-28
EP94904758A EP0683234B2 (fr) 1993-01-25 1994-01-24 Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP94904758A Division EP0683234B2 (fr) 1993-01-25 1994-01-24 Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation
EP94904758.3 Division 1994-08-04

Publications (2)

Publication Number Publication Date
EP1308461A2 EP1308461A2 (fr) 2003-05-07
EP1308461A3 true EP1308461A3 (fr) 2004-02-11

Family

ID=27455331

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02027099A Withdrawn EP1308461A3 (fr) 1993-01-25 1994-01-24 Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations
EP94904758A Expired - Lifetime EP0683234B2 (fr) 1993-01-25 1994-01-24 Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP94904758A Expired - Lifetime EP0683234B2 (fr) 1993-01-25 1994-01-24 Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation

Country Status (5)

Country Link
US (1) US5750349A (fr)
EP (2) EP1308461A3 (fr)
AT (1) ATE239797T1 (fr)
DE (1) DE69432629T3 (fr)
WO (1) WO1994017197A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP1001019A1 (fr) * 1993-10-27 2000-05-17 Athena Neurosciences, Inc. Animaux transgéniques hébergeant un gène allele APP présentant une mutation suédoise
US6365414B1 (en) 1994-08-26 2002-04-02 The General Hospital Corporation Vitro system for determining formation of Aβ amyloid
US5972634A (en) * 1994-10-19 1999-10-26 The General Hospital Corporation Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
WO1996012544A1 (fr) * 1994-10-19 1996-05-02 The General Hospital Corporation DOSAGE POUR DIAGNOSTIQUER LA MALADIE D'ALZHEIMER: EVALUATION DES ANOMALIES A$g(b)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US6114133A (en) * 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
AU4632996A (en) * 1995-02-15 1996-09-04 Takeda Chemical Industries Ltd. Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
AU1832797A (en) * 1996-01-26 1997-08-20 Trustees Of Columbia University In The City Of New York, The A polypeptide from lung extract which binds amyloid-beta peptide
US20030129589A1 (en) 1996-11-06 2003-07-10 Hubert Koster Dna diagnostics based on mass spectrometry
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
DE69839808D1 (de) * 1997-04-09 2008-09-11 Intellect Neurosciences Inc Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
AU2006202899B2 (en) * 1997-12-02 2009-10-29 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US6844148B1 (en) * 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
DK1115874T3 (da) * 1998-09-24 2009-04-20 Pharmacia & Upjohn Co Llc Alzheimer's sygdom-sekretase
EP1939297A1 (fr) 1998-09-24 2008-07-02 Pharmacia & Upjohn Company LLC Sécrétase de la maladie d'Alzheimer
US6972318B1 (en) * 1998-10-30 2005-12-06 Holtzman Jordan L Complex of a chaperone protein with amyloid
US7115410B1 (en) * 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
WO2000043791A2 (fr) * 1999-01-25 2000-07-27 Minerva Biotechnologies Corporation Detection rapide et efficace d'une agregation de proteines aberrantes dans des maladies neurodegeneratives
GB2364059B (en) 1999-02-10 2004-01-14 Elan Pharm Inc Beta-Secretase enzyme compositions and methods
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DK1409654T3 (da) * 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
US20090162883A1 (en) * 1999-09-23 2009-06-25 Pharmacia & Upjohn Company Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US6660229B2 (en) 2000-06-13 2003-12-09 The Trustees Of Boston University Use of nucleotide analogs in the analysis of oligonucleotide mixtures and in highly multiplexed nucleic acid sequencing
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
AU2002212471A1 (en) * 2000-11-01 2002-05-15 Insight Biotechnology Limited Peptides for use in the treatment of alzheimer's disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
EP1448601A4 (fr) * 2001-11-02 2006-04-26 Diagenics Internat Corp Methodes et compositions d'anticorps monoclonaux specifiques des proteines beta-amyloides
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7122374B1 (en) * 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
US20040049134A1 (en) * 2002-07-02 2004-03-11 Tosaya Carol A. System and methods for treatment of alzheimer's and other deposition-related disorders of the brain
EP1380290A1 (fr) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht La voie de la structure cross-béta et sa pertinence thérapeutique
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
CA2487528A1 (fr) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, traitement et diagnostic de maladies associees a la formation et/ou a l'agregation de la beta-amyloide
PL377769A1 (pl) * 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
KR100520495B1 (ko) * 2002-10-23 2005-10-11 한국과학기술연구원 베타아밀로이드 특이 단일 클론 항체 및 그의 제조방법
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2004100998A2 (fr) 2003-05-07 2004-11-25 General Electric Company Compositions et procedes de visualisation non effractive du beta-amyloide soluble
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
ES2246177B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP1480041A1 (fr) * 2003-05-22 2004-11-24 Innogenetics N.V. Méthode de prédiction, diagnostic et diagnostic différential de la maladie d'Alzheimer
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1666061A1 (fr) * 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Utilisation d'un anticorps
WO2005080435A1 (fr) 2004-02-20 2005-09-01 Immuno-Biological Laboratories Co., Ltd. Anticorps monoclonal et utilisation de celui-ci
CA2575663C (fr) * 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Anticorps anti peptide amyloide beta, et leurs procedes d'utilisation
BRPI0518151A2 (pt) * 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
PE20061401A1 (es) * 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
ES2259270B1 (es) * 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
EP1907864A2 (fr) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Méthodes de détermination de l'effet d'un traitement sur la teneur d'une protéine à structure croisee beta, sélection des traitements et leurs utilisations
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
CA2615028A1 (fr) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Composes de liaison de structures .beta.-croisees
RU2008120027A (ru) * 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) Анти-addl моноклональное антитело и его применение
KR101667623B1 (ko) 2005-11-30 2016-10-19 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
CN101351476B (zh) 2005-12-12 2013-04-03 豪夫迈·罗氏有限公司 抗体可变区的糖基化
RS53291B (sr) 2005-12-12 2014-08-29 Ac Immune S.A. Beta 1-42 specifična monoklonska antitela sa terapeutskim svojstvima
EP2007800A1 (fr) * 2006-03-17 2008-12-31 Crossbeta Biosciences B.V. Procédés de liaison de structures bêta croisées avec des molécules chaperonnes
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CL2007002070A1 (es) 2006-07-14 2008-02-08 Ac Immune S A Genentech Inc Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade
US20100104577A1 (en) * 2006-10-10 2010-04-29 Golde Todd E Methods and materials related to anti-a (beta) antibodies
US7745222B2 (en) * 2006-10-13 2010-06-29 General Electric Company Amyloid binding assays
DK2104682T3 (en) * 2007-01-11 2017-01-16 Michael Bacher DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES
EP1944315A1 (fr) * 2007-01-11 2008-07-16 Philipps-Universität Marburg Prophylaxe et thérapie de la maladie d'Alzheimer et d'autres désordres neurologiques
US20110020347A1 (en) 2007-02-09 2011-01-27 Takahiko Hara Anti-brak (cxcl14) human monoclonal antibody and use thereof
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
TW201518320A (zh) * 2007-06-12 2015-05-16 Ac Immune Sa 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
EP2182983B1 (fr) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Traitement de maladies amyloïdogéniques avec anti-abeta anticorps humanise
WO2009043103A1 (fr) * 2007-10-02 2009-04-09 Csl Limited Procédé de purification d'anticorps thérapeutique et procédé d'utilisation
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2058001A1 (fr) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Amélioration de l'immunogénicité des antigènes
EP2058000A1 (fr) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Compositions immunogènes capables d'activer des cellules T
MX2010006422A (es) * 2007-12-11 2010-06-25 Glaxo Group Ltd Proteinas de union a antigenos.
JP5295229B2 (ja) * 2008-05-08 2013-09-18 武田薬品工業株式会社 Ａβオリゴマー測定法
US20110092445A1 (en) * 2008-07-25 2011-04-21 Abbott Laboratories Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses
EP2149380A1 (fr) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Compositions d'immunothérapie vétérinaire pour le disfonctionnement cognitif associé à l'âge
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2258398A1 (fr) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Conjugués d'albumine-peptide d'amyloide et leurs utilisations
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2478365A1 (fr) * 2009-09-18 2012-07-25 Probiodrug AG Nouvel essai pour la détection de peptides bêta amyloïdes
EP2542549B1 (fr) 2010-03-03 2016-05-11 Probiodrug AG Inhibiteurs de glutaminyl cyclase
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CA2806909C (fr) 2010-07-30 2019-12-17 Ac Immune S.A. Anticorps humanises surs et fonctionnels
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2691393B1 (fr) 2011-03-31 2016-09-14 Pfizer Inc Nouvelles pyridones bicycliques
EP2511296A1 (fr) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Anticorps, kit et procédé pour déterminer des peptides amyloïdes
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
WO2013012811A2 (fr) 2011-07-19 2013-01-24 New York University Modulation immunothérapeutique de maladie amyloïdogène à l'aide de protéines et peptides polymérisés non fibrillogènes, non amyloïdogènes
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease
WO2013030713A1 (fr) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
EP2852597B1 (fr) 2012-05-04 2016-06-08 Pfizer Inc Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CA2882389A1 (fr) 2012-09-20 2014-03-27 Pfizer Inc. Composes d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitues
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (fr) 2013-02-13 2017-08-09 Pfizer Inc Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EA201591360A1 (ru) 2013-02-19 2016-03-31 Пфайзер Инк. Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
CA2925743C (fr) 2013-10-04 2018-03-06 Pfizer Inc. Nouvelles pyridinones bicycliques utilisees comme modulateurs de gamma-secretase
CA2933767C (fr) 2013-12-17 2018-11-06 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituees et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituees en tant qu'inhibiteurs de la lrrk2
AU2015242330B2 (en) 2014-04-01 2017-08-17 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
EA030085B1 (ru) 2014-04-10 2018-06-29 Пфайзер Инк. 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
AP2017009744A0 (en) 2014-08-06 2017-02-28 Pfizer Imidazopyridazine compounds
WO2016125048A1 (fr) 2015-02-03 2016-08-11 Pfizer Inc. Nouveaux pyridopyrazinediones cyclopropabenzofuranyl
CA2989456C (fr) 2015-06-17 2022-01-04 Pfizer Inc. Composes tricycliques et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
JP6691144B2 (ja) 2015-06-24 2020-04-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 目的に合わせた親和性を有する抗トランスフェリンレセプター抗体
MX377305B (es) 2015-09-14 2025-03-07 Pfizer DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
WO2017051276A1 (fr) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
EP3353182A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
EP3356406A1 (fr) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA3015166C (fr) 2016-02-23 2021-08-03 Pfizer Inc. Composes 6,7-dihydro-5 h-pyrazolo [5,1-b] [1,3]oxazine-2-carboxamide
AU2017286868B2 (en) 2016-07-01 2021-11-11 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
MX2019010756A (es) 2017-03-10 2020-01-20 Pfizer Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
WO2018163030A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Dérivés d'imidazo [4,5-c] quinoléine substitués cycliques
EP3634978A1 (fr) 2017-06-07 2020-04-15 Adrx, Inc. Inhibiteur d'agrégation de tau
ES2937236T3 (es) 2017-06-22 2023-03-27 Pfizer Derivados de dihidro-pirrolo-piridina
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PL3768669T3 (pl) 2018-03-23 2023-07-03 Pfizer Inc. Pochodne azaspiro piperazyny
MY203453A (en) 2018-07-17 2024-06-28 Shanghai hengrui pharmaceutical co ltd Anti-abeta antibody, antigen-binding fragment thereof and application thereof
CA3176743A1 (fr) * 2019-04-04 2020-10-08 The Royal Institution For The Advancement Of Learning / Mcgill University Utilisation de a.beta.34 pour evaluer la progression de la maladie d'alzheimer
US20230021187A1 (en) 2019-11-19 2023-01-19 Foundation For Biomedical Research And Innovation At Kobe Cross-linked product of amyloid-b protein (ab) as potential substitute for amylospheroids (aspd) and analysis of aspd
WO2022182658A1 (fr) 2021-02-23 2022-09-01 Hoth Therapeutics, Inc. Utilisation d'aprépitant pour le traitement de la maladie d'alzheimer
WO2025145091A1 (fr) 2023-12-29 2025-07-03 Pfizer Inc. Formes cristallines d'un modulateur muscarinique m4 du récepteur et méthodes de traitement de maladies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009699A1 (fr) * 1990-11-27 1992-06-11 L.F. Will & Cie (Belgique) Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (fr) * 1987-10-08 1997-03-25 Ronald E. Majocha Anticorps pour peptide a4-amyloide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009699A1 (fr) * 1990-11-27 1992-06-11 L.F. Will & Cie (Belgique) Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
WO1994017197A1 (fr) 1994-08-04
DE69432629D1 (de) 2003-06-12
EP0683234B2 (fr) 2007-06-06
EP0683234B1 (fr) 2003-05-07
ATE239797T1 (de) 2003-05-15
EP1308461A2 (fr) 2003-05-07
EP0683234A4 (fr) 1998-03-11
DE69432629T3 (de) 2008-01-17
US5750349A (en) 1998-05-12
EP0683234A1 (fr) 1995-11-22
DE69432629T2 (de) 2004-03-25

Similar Documents

Publication Publication Date Title
EP1308461A3 (fr) Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations
EP0911390A3 (fr) Protéine kinases comme outils pour le diagnostic et le traitement de la maladie d' Alzheimer
IL137176A0 (en) Antibodies to 4dr and uses thereof
BG103522A (en) Compositions and methods for ob type protein syntheses
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
WO2000073452A3 (fr) Compositions et methodes de traitement de maladies liees a l'immunite
WO1996002645A3 (fr) Ligand de htk
EP0673255A4 (fr) Anticorps monoclonal se liant specifiquement a l'endothelium vasculaire tumoral.
WO2003066661A3 (fr) Anticorps humains du dr4 et utilisations
EP0350690A3 (fr) Neutralisation des propriétés toxiques in vitro et in vivo du TNF-alfa par anticorps monoclonaux et fragments dérivés
PT1181319E (pt) Anticorpos quiméricos contra dr4 e suas utilizações
EP0090581A3 (fr) Petits peptides specifiques des antigènes de la fièvre aphteuse
YU79491A (sh) Varijantni cd44-površinski proteini, dna-sekvence koje ih kodiraju i antitela protiv ovih proteina
Erickson et al. Purification and partial characterization of a 65-kDa platelet aggregation-associated protein antigen from the surface of Streptococcus sanguis.
WO2001018550A3 (fr) Determination de proteines de liaison a am et association d'adrenomedulline (am)
WO2001064877A3 (fr) Gene humain de la schizophrenie
WO1996013592A3 (fr) Proteine kinase npk-110
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
WO1999014241A3 (fr) Traitement d'affections liees aux fonctions immunitaires et compositions correspondantes
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
WO2001057219A3 (fr) Cytokines mammaliennes, leurs recepteurs, reactifs et procedes correspondants
WO2001040465A3 (fr) Compositions et procedes de traitement de maladies d'ordre immunologique
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2000015797A3 (fr) Compositions et methodes de traitement des maladies relatives au syteme immunitaire

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0683234

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ASAMI, ASANO

Inventor name: KITADA, CHIEKO

Inventor name: SUZUKI, NOBUHIRO

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12R 1:91 J

Ipc: 7C 12P 21/08 J

Ipc: 7C 07K 16/18 A

Ipc: 7C 12P 21/08 B

18W Application withdrawn

Effective date: 20040117